Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Another BACE inhibitor fails in phase III trials
  2. Arrowhead ends enrolment in AROAAT1001 trial
  3. Agios starts Activate trial for pyruvate kinase deficiency
  4. Teva announces change in ENFORCE Phase III trial of fremanezumab
  5. MorphoSys presents data from Phase II trial of blood cancer drug

Latest Content

Another BACE inhibitor fails in phase III trials

On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the decision to terminate AMARANTH (NCT02245737) and the DAYBREAK-ALZ (NCT02783573) trials after an independent data monitoring committee concluded they were unlikely to meet primary endpoints based on interim analysis. The related AMARANTH extension trial (NCT02972658) will also be discontinued. This termination is preceded by recent failures of BACE inhibitors in late stage clinical development for the treatment of AD.

Sol-Gel doses first patient in Phase III trial of Epsolay

Sol-Gel Technologies has dosed the first patient in a pivotal Phase III clinical trial programme designed to analyse the safety and efficacy of Epsolay (formerly VERED) for the treatment of patients with papulopustular rosacea, also known as subtype II rosacea.

Avedro starts enrolment in ACP-KXL-308 trial

Avedro has started patient enrolment in the ACP-KXL-308 trial, a pivotal Phase lll clinical study to examine the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking (CXL) procedure to treat patients with progressive keratoconus.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top